Skip to main content
. 2023 Apr 25;381:e074572. doi: 10.1136/bmj-2022-074572

Fig 3.

Fig 3

Hazard ratio and absolute risk reduction of molnupiravir compared with no treatment on individual post-acute sequelae. Post-acute outcomes were ascertained 30 days after a first SARS-CoV-2 positive test result between 5 January 2022 and 15 January 2023 until end of follow-up. Length of shaded area represents risk reduction per 100 people at 180 days, Whiskers represent 95% confidence intervals (CIs)